McKesson Corporation $MCK Stock: Lazari Capital Management Inc. Grows Position

Lazari Capital Management Inc. increased its holdings in shares of McKesson Corporation (NYSE:MCK) by 165.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,468 shares of the company’s stock after purchasing an additional 914 shares during the period. Lazari Capital Management Inc.’s holdings in McKesson were worth $1,253,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in McKesson in the 2nd quarter valued at about $8,156,743,000. Bank of America Corp DE increased its stake in shares of McKesson by 2.4% in the first quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock worth $1,331,552,000 after buying an additional 35,916 shares during the last quarter. Swedbank AB boosted its stake in McKesson by 13.5% during the 1st quarter. Swedbank AB now owns 1,005,610 shares of the company’s stock valued at $870,215,000 after acquiring an additional 119,327 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of McKesson by 3.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company’s stock valued at $697,096,000 after purchasing an additional 29,747 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in McKesson during the second quarter valued at approximately $656,566,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MCK shares. Citigroup raised their price target on shares of McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Barclays increased their price target on McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Evercore reiterated an “outperform” rating and issued a $950.00 target price (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Mizuho increased their target price on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, Bank of America raised their target price on shares of McKesson from $950.00 to $1,050.00 in a research note on Thursday, August 6th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $997.12.

Insider Activity

In related news, Director Bradley E. Lerman sold 301 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Francisco Fraga sold 800 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $995.80, for a total transaction of $796,640.00. Following the completion of the transaction, the executive vice president owned 5,423 shares in the company, valued at approximately $5,400,223.40. This represents a 12.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,212 shares of company stock worth $1,164,182. 0.06% of the stock is owned by corporate insiders.

McKesson Price Performance

Shares of NYSE:MCK traded up $10.16 on Tuesday, reaching $1,020.59. 312,383 shares of the company traded hands, compared to its average volume of 926,526. McKesson Corporation has a fifty-two week low of $723.68 and a fifty-two week high of $1,024.56. The stock has a market capitalization of $118.99 billion, a PE ratio of 27.33, a P/E/G ratio of 2.00 and a beta of 0.30. The company’s 50 day moving average is $900.34 and its 200-day moving average is $838.37.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The business had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. During the same quarter last year, the company posted $8.26 EPS. McKesson’s revenue for the quarter was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, analysts expect that McKesson Corporation will post 44.71 EPS for the current year.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Analyst targets continue to rise. UBS raised its price target to $1,200, while Leerink increased its target from $1,030 to $1,070. These revisions suggest analysts see additional upside for McKesson’s pharmaceutical distribution and healthcare-services businesses. UBS raises McKesson price target Leerink raises McKesson price target
• Positive Sentiment: Strong operating performance supports investor sentiment. The company’s latest quarterly EPS beat consensus by $0.37, and revenue exceeded estimates by approximately $1.5 billion. Analysts forecast about $44.71 in EPS for the current fiscal year.
• Neutral Sentiment: Mizuho raised its target but maintained a Neutral rating. Mizuho lifted its price objective from $905 to $1,020, essentially aligning it with McKesson’s current valuation. The upgrade in target is constructive, but the Neutral rating indicates limited near-term upside from Mizuho’s perspective. Mizuho adjusts McKesson price target
• Negative Sentiment: An executive sold shares. EVP Francisco Fraga sold 800 shares worth approximately $796,640, reducing his direct holdings by 12.86%. However, the transaction was made under a pre-arranged Rule 10b5-1 trading plan, making it a relatively weak negative signal.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.